Caplin point laboratories Limited has announced a post-results conference call with analysts, fund houses, and investors to discuss its financial performance for the quarter ended December 31, 2025. The earnings call is scheduled for Thursday, February 05, 2026, at 16:00 hrs IST.

Regulatory Compliance and Announcement Details

The company made this announcement on January 29, 2026, in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The notification was formally communicated to both BSE Limited and the National Stock Exchange of India Ltd through their respective corporate relationship departments.

Management Representation

The Q3FY26 earnings conference call will feature key members of Caplin Point Laboratories' senior management team:

Conference Call Access Information

Participants can join the earnings call through multiple access methods. The conference provides universal access numbers including +91 22 6280 1116 and +91 22 7115 8017 for domestic participants.

International Participation Options

International participants can access the call through dedicated toll-free numbers:

Coordination and Contact Details

The conference call is being coordinated by Dolat Capital Market Pvt. Ltd. Participants requiring additional information can contact Kapil Yadav, Director Equity Sales & Corporate Access, or Candice Pareira, AVP Research, at their respective contact numbers and email addresses.

Important Notes

The company has indicated that the schedule of the meeting is subject to change due to exigencies on the part of analysts or the company. The announcement was digitally signed by Venkatram G, General Counsel & Company Secretary, with membership number A23989, ensuring proper authorization and compliance with regulatory requirements.

Caplin point laboratories subsidiary Caplin Steriles Limited has secured final approval from the United States Food and Drug Administration (USFDA) for its Methylprednisolone Acetate Injectable Suspension, marking another milestone in the company's US market expansion strategy.

USFDA Approval Details

The approval covers the Abbreviated New Drug Application (ANDA) for Methylprednisolone Acetate Injectable Suspension USP in two strengths - 40mg/mL and 80mg/mL Single Dose vials. This generic version serves as a therapeutic equivalent to the Reference Listed Drug (RLD) DEPO-MEDROL manufactured by Pfizer Inc., USA.

Therapeutic Applications

Methylprednisolone Acetate Injectable Suspension functions primarily as an anti-inflammatory treatment across diverse medical conditions. The medication addresses multiple therapeutic areas including:

• Allergic states and dermatologic diseases
• Endocrine disorders and gastrointestinal diseases
• Hematologic diseases and ophthalmic conditions
• Respiratory diseases and rheumatic disorders

According to IQVIA™ (IMS Health) data, the approved product had US sales of approximately $57.4 million for the 12-month period ending November 2025, representing a substantial market opportunity for Caplin Steriles.

Company Portfolio and Capabilities

Caplin Steriles Limited operates as a fast-growing sterile product manufacturing company with approvals from multiple regulatory agencies including US FDA, EU-GMP, ANVISA and INVIMA. The subsidiary has demonstrated strong development capabilities with 53 ANDAs filed in the USA independently and through partnerships, achieving 50 approvals including acquired ANDAs.

The company maintains an active pipeline of 55+ simple and complex Injectable and Ophthalmic products planned for filing over the next 4 years. Additionally, Caplin Steriles has secured multiple product approvals in non-US markets across various countries.

Corporate Structure and Recognition

Caplin Point Laboratories Limited operates with a unique business model focused predominantly on emerging markets in Latin America and Africa. The parent company has achieved consistent high-quality growth in cash flows, profitability and revenues over 15 years. Notable recognition includes appearing on Forbes "Asia's 200 Best Under a Billion" list seven times in the last 10 years, along with receiving "The Emerging Company of 2018" and "Business Excellence Award for 2019" from Economic Times.

The group structure includes Caplin One Labs Limited (COL), another subsidiary operating an oncology unit in Kakkalur in its second year of operations. COL holds 5 approved ANDAs for Injectable and Ophthalmic products while working on various projects in different completion stages for generic and specialty products across regulated and other markets.